Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

ClinicalTrials.gov ID: NCT01754935

Public ClinicalTrials.gov record NCT01754935. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VX-509 Using Magnetic Resonance Imaging and Arthroscopic Biopsies in Subjects With Active Rheumatoid Arthritis on Stable Disease-Modifying Antirheumatic Drugs

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The current study is designed to evaluate the safety and efficacy, including MRI imaging, across a range of VX-509 doses in subjects with active rheumatoid arthritis (RA) who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs).

Study identification

NCT ID
NCT01754935
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
43 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2012
Primary completion
Dec 31, 2013
Completion
Jan 31, 2014
Last update posted
May 18, 2015

2013 – 2014

United States locations

U.S. sites
21
U.S. states
14
U.S. cities
21
Facility City State ZIP Site status
Vertex Investigational Site Stanford California
Vertex Investigational Site Upland California
Vertex Investigational Site Fort Lauderdale Florida
Vertex Investigational Site Venice Florida
Vertex Investigational Site West Palm Beach Florida
Vertex Investigational Site Canton Georgia
Vertex Investigational Site Decatur Georgia
Vertex Investigational Site Kansas City Kansas
Vertex Investigational Site Elizabethtown Kentucky
Vertex Investigational Site Frederick Maryland
Vertex Investigational Site Lincoln Nebraska
Vertex Investigational Site Rochester New York
Vertex Investigational Site Greenboro North Carolina
Vertex Investigational Site Duncansville Pennsylvania
Vertex Investigational Site Charleston South Carolina
Vertex Investigational Site Memphis Tennessee
Vertex Investigational Site Katy Texas
Vertex Investigational Site San Antonio Texas
Vertex Investigational Site Webster Texas
Vertex Investigational Site Seattle Washington
Vertex Investigational Site Spokane Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01754935, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 18, 2015 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01754935 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →